Motzer, Robert J.
Escudier, Bernard
Powles, Thomas
Scheffold, Christian
Choueiri, Toni K. http://orcid.org/0000-0002-9201-3217
Article History
Received: 1 December 2017
Revised: 15 February 2018
Accepted: 28 February 2018
First Online: 26 March 2018
Competing interests
: R.M. has received personal fees for an advisory/consulting role from Pfizer, Novartis, Eisai, Exelixis, and research funding from Exelixis and from Bristol-Myers Squibb, Pfizer, Genentech/Roche, Eisai, Novartis, outside the submitted work. B.E. has received personal fees for an advisory/consulting role from Novartis, Bristol-Myers Squibb, Roche, Exelixis, Ipsen, Acceleron Pharma, Bayer, and research funding from Novartis and Bristol-Myers Squibb, outside the submitted work. T.P. has received personal fees for an advisory/consulting role from AstraZeneca, Bristol-Myers Squibb, Genentech/Roche, Merck, Exelixis and research funding from AstraZeneca/MedImmune, Roche/Genentech, outside the submitted work. C.S. is an employee of Exelixis. T.C. has received personal fees for an advisory/consulting role from Pfizer, GlaxoSmithKline, Novartis, Merck, Bayer, Eisai, Roche, Prometheus Labs Inc, Foundation Medicine Inc., Bristol-Myers Squibb, and institutional research funding from Exelixis and from Pfizer, GlaxoSmithKline, Novartis, Bristol-Myers Squibb, Merck, Roche, AstraZeneca, Tracon, and Peloton, outside the submitted work.
: The study was conducted according to the Good Clinical Practice guidelines and the Declaration of Helsinki. The protocol was approved by the institutional review board or ethics committee at each centre, and written informed consent was obtained for all patients.